Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has issued an update.
MedPlus Health Services Ltd. disclosed that its subsidiary, Optival Health Solutions, has received a two-day suspension of a drug license for one of its stores located at Bidadi Bus Stand in Karnataka. The suspension was ordered by the Assistant Director of the Drugs Control Administration, Bangalore South Circle, under Rule 65 of the Drugs and Cosmetics Act, 1940, and corresponding Rules of 1945, resulting in an estimated potential revenue loss of Rs 2.88 lakh but affecting only a single outlet in its wider network.
The company has indicated that details of the regulatory action will be made available on its website and on the stock exchanges where its shares are listed. While the monetary impact appears limited and confined to one store, the incident underscores ongoing regulatory scrutiny in the pharmaceutical retail sector and highlights the importance of strict compliance with drug licensing norms for MedPlus and its subsidiaries.
More about MedPlus Health Services Ltd.
MedPlus Health Services Ltd. is a pharmacy retail and healthcare services company operating through a network of stores across India. Its subsidiary Optival Health Solutions Private Limited manages retail outlets that dispense pharmaceutical products, health supplies, and related services, with a strong presence in states including Karnataka.
Average Trading Volume: 17,362
Technical Sentiment Signal: Strong Buy
Current Market Cap: 102.3B INR
For an in-depth examination of MEDPLUS stock, go to TipRanks’ Overview page.

